• Explore /
  • Poster
  • / Interpreting survival outcomes for African-American (AA) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T (SIP-T) with number needed to treat to benefit (NNTB).

Interpreting survival outcomes for African-American (AA) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T (SIP-T) with number needed to treat to benefit (NNTB).

Abstract Poster

Authors

null

Kelvin A. Moses

Vanderbilt University School of Medicine, Nashville, TN

Kelvin A. Moses , Scott C. Flanders , Matthew Harmon , Nancy N. Chang , Walter Rayford , David I. Quinn , A. Oliver Sartor

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT00065442

Citation

J Clin Oncol 37, 2019 (suppl 7S; abstr 222)

DOI

10.1200/JCO.2019.37.7_suppl.222

Abstract #

222

Poster Bd #

K1

Abstract Disclosures

Similar Posters

First Author: David I. Quinn

First Author: David D. Chism

First Author: Michael J. Morris

First Author: Michael J. Morris